GSK to acquire US biotech group behind food allergy drug
Digest more
Zacks Investment Research on MSN
GSK to boost respiratory & immunology pipeline with $2.2B RAPT buyout
GSK plc GSK announced that it has entered into a definitive agreement to acquire California-based biotech RAPT Therapeutics ...
The star of the acquisition, anti-IgE antibody ozureprubart, is being tested as a prophylactic treatment for food allergies, ...
GSK acquires Rapt Therapeutics for $2.2B. Stock surges 65% as pharma giant gains access to phase 2b food allergy treatment ...
RAPT Therapeutics, Inc. is being acquired by GSK plc for $2.2B as ozureprubart targets IgE disorders with 8–12 week dosing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback